How do you approach DMT choice in a patient with MS with a history of cancer?

Based on this review (Melamed and Lee, PMID 31998289), patients with MS on several DMTs may be at higher risk for certain cancers. How does this play into your decisions regarding DMT selection?

Answer from: at Academic Institution

The overall cancer risk for many of the newer DMTs (both oral and intravenous) is low though usually slightly higher than that expected in the general population. The exception might be thyroid cancers associated with alemtuzumab. I generally ask about personal cancer risk, especially skin an...

Comments

at PeaceHealth
In a > 40-year-old patient with 8-month history...

Please select the option that best describes you:

How do you approach DMT choice in a patient with MS with a history of cancer?

Related Questions